vs
Side-by-side financial comparison of ACHIEVE LIFE SCIENCES, INC. (ACHV) and IMMUCELL CORP (ICCC). Click either name above to swap in a different company.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $5.5M | ||
| Q2 25 | — | $6.4M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | — | $6.0M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $7.3M | ||
| Q4 23 | — | $5.1M |
| Q3 25 | — | $-139.7K | ||
| Q2 25 | — | $501.9K | ||
| Q1 25 | — | $1.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-701.7K | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-437.9K | ||
| Q4 23 | — | — |
| Q3 25 | — | 42.9% | ||
| Q2 25 | — | 43.7% | ||
| Q1 25 | — | 41.6% | ||
| Q4 24 | — | 36.5% | ||
| Q3 24 | — | 26.3% | ||
| Q2 24 | — | 22.5% | ||
| Q1 24 | — | 31.6% | ||
| Q4 23 | — | 24.7% |
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 8.8% | ||
| Q1 25 | — | 13.9% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | — | -25.3% | ||
| Q1 24 | — | -4.1% | ||
| Q4 23 | — | -19.7% |
| Q3 25 | — | -2.5% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 17.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -11.7% | ||
| Q2 24 | — | -28.0% | ||
| Q1 24 | — | -6.0% | ||
| Q4 23 | — | — |
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $0.06 | ||
| Q1 25 | — | $0.16 | ||
| Q4 24 | — | $0.09 | ||
| Q3 24 | — | $-0.09 | ||
| Q2 24 | — | $-0.20 | ||
| Q1 24 | — | $-0.06 | ||
| Q4 23 | — | $-0.15 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
